D.E. Shaw & Co
ENTA icon

D.E. Shaw & Co’s Enanta Pharmaceuticals ENTA Stock Holding History

D.E. Shaw & Co’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,000
Closed -$580K – 3780
2018
Q2 		$580K Hold
5,000
– – ﹤0.01% 3031
2018
Q1 		$405K Buy
+5,000
New +$385K ﹤0.01% 2982

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's ENTA Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Enanta Pharmaceuticals (ENTA) stake by 58% in Q1 2026, selling an estimated $1.3M and leaving 70,884 shares worth $895K. The position accounts for ﹤0.01% of the portfolio, ranked #3517.

D.E. Shaw & Co first reported a position in ENTA in Q3 2014 and has held it in 37 quarters since. The position peaked at $9.96M in Q1 2024. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • D.E. Shaw & Co held 70,884 shares of Enanta Pharmaceuticals worth $895K as of Q1 2026.
  • D.E. Shaw & Co sold 96,830 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.3M.
  • Enanta Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3517 holding.
  • D.E. Shaw & Co first reported a position in Enanta Pharmaceuticals in Q3 2014 and has held it in 37 quarters since.
  • D.E. Shaw & Co's Enanta Pharmaceuticals position peaked at $9.96M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.